Holen Sie sich die Stockscreener-App
1.45
3.57%
0.05
Handel nachbörslich:
1.39
-0.06
-4.14%
Bluejay Diagnostics Inc Aktie (BJDX) Neueste Nachrichten
Form 4 Bluejay Diagnostics Inc For: 10 July By Investing.com - Investing.com Nigeria
Bluejay Diagnostics (NASDAQ: BJDX) shows Bank of America entities as 10% owners - Stock Titan
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) sees 8 shares reported by Bank of America - Stock Titan
Bluejay Diagnostics Inc. (BJDX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
BJDX Stock Pulls Back As Traders Eye Cash Runway - StocksToTrade
BJDX Stock Slides As Traders Gauge Cash Runway And Volatility - timothysykes.com
BJDX Stock Pulls Back As Traders Eye Support Levels - StocksToTrade
BJDX Stock Slides As Traders Study Volatile Chart - timothysykes.com
BJDX Stock Slides As Traders Focus On Cash Runway And Volatility - StocksToTrade
Bluejay Diagnostics stock rally meets a June warrant wall after pre-market churn - TechStock²
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
BJDX Stock Slides As Traders Watch Support Levels - timothysykes.com
Bluejay Diagnostics Advances Symphony IL-6 Sepsis Pilot, Keeping Investor Focus on ER Diagnostics - TipRanks
Market Movers | Winners: TRNR, DCOY, ATLN | Losers: BJDX, EVMN, CELZ - Trefis
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
[EFFECT] Bluejay Diagnostics, Inc. SEC Filing - Stock Titan
Bluejay Diagnostics (BJDX) Falls 11.5% as Selling Pressure Intensifies; Support at $2.78 in FocusSentiment Divergence - dars.gov.et
Bluejay Diagnostics (BJDX) registers 11.2M resale shares; warrants tied to cash proceeds - Stock Titan
Price to sales forward of Bluejay Diagnostics, Inc. – NASDAQ:BJDX - TradingView
Enterprise value to revenue forward of Bluejay Diagnostics, Inc. – NASDAQ:BJDX - TradingView
Enterprise value to EBIT forward of Bluejay Diagnostics, Inc. – NASDAQ:BJDX - TradingView
Enterprise value to EBITDA forward of Bluejay Diagnostics, Inc. – NASDAQ:BJDX - TradingView
BJDX Q4 2023 Earnings: EPS Misses Estimates by a Wide Margin Amid Operational ChallengesCapex Guidance - dars.gov.et
BJDX Q4 2023 Earnings: Significant EPS Miss as Diagnostics Firm Reports No Revenue; Shares RallyDownward Estimate Revision - dars.gov.et
Bluejay Diagnostics Inc (BJDX) Institutional Confidence - TradingKey
Bluejay Diagnostics (BJDX) Surges 10.7% as Rally Tests Key ResistanceGEX Level - dars.gov.et
Bluejay Diagnostics Inc (BJDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BJDX SEC FilingsBluejay Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Bluejay Diagnostics | SCHEDULE 13D: Others - Moomoo
Bluejay Diagnostics Inc (BJDX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bluejay Diagnostics Inc (BJDX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bluejay Diagnostics Inc (BJDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bluejay Diagnostics Inc (BJDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bluejay Diagnostics (NASDAQ: BJDX) registers 11.2M resale shares from warrant holders - Stock Titan
Bluejay Diagnostics Inc (BJDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bluejay Diagnostics Inc (BJDX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bluejay Diagnostics Inc (BJDX) Valuation: PE, PB & Fair Value Analysis - TradingKey
BJDX Q4 2023 Earnings: Wider-than-Expected Loss Deepens as Pre-Revenue Diagnostics Firm Navigates Cost PressuresEarnings Call Q&A - newsline.com
Bluejay Diagnostics Inc. (BJDX) Q4 2023 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineLong-Term Guidance - newsline.com
BJDX Q4 2023 Earnings: EPS Misses Estimates by Wide Margin as No Revenue ReportedFull Year Guidance - newsline.com
BJDX Q4 2023 Earnings: Significant EPS Miss Amid Pre-Revenue StageMargin Guidance - newsline.com
Bluejay Diagnostics Shareholders Approve Stock Plan and Flexibility - TipRanks
Bluejay Diagnostics (NASDAQ: BJDX) expands stock plan and wins reverse split approval - Stock Titan
BLUEJAY DIAGNOSTICS INC (BJDX) Stock Chart - ChartMill
Bluejay Diagnostics Announces $23.6 Million Private Placement to Extend Cash Runway Beyond FDA Submission - Minichart
Bluejay Diagnostics Completes Private Placement to Extend Runway - TipRanks
Bluejay Diagnostics Raises $7.7 Million in Private Placement, Issues Pre-Funded and 5-Year Warrants - TradingView
Bluejay Diagnostics (NASDAQ: BJDX) closes $8.5M warrant-backed financing - Stock Titan
Bluejay Diagnostics completes private placement that raised USD 8.5M - Medical Buyer
Bluejay Diagnostics closes $8.5 million private placement By Investing.com - Investing.com Australia
Bluejay Diagnostics (BJDX) Drops 9.43% as Stock Tests Key Support at $4.56Covered Call Trade - dars.gov.et
Bluejay Diagnostics closes $8.5 million private placement - Investing.com
Bluejay Diagnostics, Inc. Closes $8.5 Million Private Placement to Extend Cash Runway for FDA Approval and Commercialization - Moomoo
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance Australia
[SCHEDULE 13G] Bluejay Diagnostics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Press Release: Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Moomoo
What's going on with Bluejay Diagnostics shares on Wednesday? - MSN
Bluejay Diagnostics, Inc. announced that it has received $8.500007 million in funding - marketscreener.com
BJDX Q4 2023 Earnings: Significant EPS Miss Despite Revenue Absence Drives Stock SurgeTech Earnings Analysis - newsline.com
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):